Category

Archives

Akt

Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancer

47 views | Jul 12 2022

Lindsey Buckingham et al. found that IPAT significantly inhibited cell proliferation and colony formation in a dose-dependent manner in USC cells. [Read the Full Post]

The close interaction between hypoxia-related proteins and metastasis in pancarcinomas

49 views | Jul 11 2022

Andrés López-Cortés et al. identified 23 drugs enrolled in clinical trials focused on metastatic disease treatment. [Read the Full Post]

Vasorelaxant effect of curcubisabolanin A isolated from Curcuma longa through the PI3K/Akt/eNOS signaling pathway

125 views | May 25 2022

Jin-Feng Chen et al. demonstrated that the vasorelaxant effect of curcubisabolanin A was partially endothelium-dependent. [Read the Full Post]

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells

278 views | Apr 01 2022

Alessio Malacrida et al. thought that rigosertib could be a potential therapeutic option, alone or in combination with radiations, for nonresectable patients with cholangiocarcinoma. [Read the Full Post]

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair

259 views | Mar 31 2022

Alessio Malacrida et al. hypothesized the mechanism of the action of Rigosertib against cholangiocarcinoma EGI-1 cells, highlighting the importance of proteins involved in the regulation of cell cycles. [Read the Full Post]

Unfolded protein response-induced expression of long noncoding RNA Ngrl1 supports peripheral axon regeneration by activating the PI3K-Akt pathway

121 views | Mar 06 2022

Dong Wang found that unfolded protein response-induced Ngrl1 expression supports the intrinsic control of peripheral axon regeneration by modulating the activation of the PI3K-Akt pathway following SNC. [Read the Full Post]

Inhibitor GSK690693 extends Drosophila lifespan via reduce AKT signaling pathway

798 views | Jan 27 2022

Xingyi Cheng et al. indicated that GSK690693 might become an effective compound for anti-aging intervention. [Read the Full Post]

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

278 views | Nov 08 2021

Shannon N Westin et al. found that the combination of olaparib and capivasertib was associated to no serious adverse events and demonstrated durable activity in ovarian, endometrial, and breast cancers, with promising responses in endometrial cancer. [Read the Full Post]

ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins

380 views | Aug 19 2021

Clara Alcon et al. found that the anti-apoptotic proteins BCL-xL and MCL-1 were crucial for ER+ breast cancer cells resistance to therapy. [Read the Full Post]

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using Two Methods of Classification of Hepatic Function

398 views | Aug 18 2021

Rucha Sane et al. showed that no dosage adjustment was required for ipatasertib when treating patients with mild hepatic impairment, whereas a dose reduction would be recommended for subjects with moderate or severe hepatic impairment. [Read the Full Post]